Company Interview / Control Bionics jumping towards record revenue

Jeremy Steele, CEO of Control Bionics (ASX:CBL) provides a trading update, showing a 14% revenue increase to nearly $5.5 million. He says the company focuses on EMG technology to aid communication for patients with conditions like motor neurone disease, ALS, and cerebral palsy.

Jeremy states the firm is innovating with products like the Neuro Node and Neuro Strip, offering new opportunities in sports, rehabilitation, and hospital environments. Control Bionics' (ASX:CBL) autonomous wheelchair, Drover, aims to improve independence for people with mobility challenges.

The company focuses on growth in the US and Europe, securing new distribution agreements. Jeremy notes opportunities in the UK's NHS, aiming for financial growth and stock recovery amid challenging biotech market conditions.